Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

Fig. 2

Comparison of PFS curves according to the mutation status of a defined gene or gene combination upon receiving cetuximab-based therapy. a. Comparison of PFS curves of the SMAD4mut group and the SMAD4wt group. b. Comparison of PFS curves of the NF1mut group and the NF1wt group. c. Comparison of PFS curves of the SMAD4mut or NF1mut group comparing with the SMAD4wt and NF1wt group. The P value is calculated according to Gehan-Breslow-Wilcoxon test. Figures are made using GraphPad Prism 5

Back to article page